Introduction {#section5-1756283X17725977}
============

Nonalcoholic fatty liver disease (NAFLD) has become a widespread epidemic, with global prevalence estimates ranging approximately from 22% to 29% in the general population.^[@bibr1-1756283X17725977]^ It encompasses a broad clinicopathologic spectrum from simple steatosis to nonalcoholic steatohepatitis, and can even progress to hepatocellular carcinoma.^[@bibr2-1756283X17725977]^ Besides being the most common cause of liver disease, accumulating evidence indicates that NAFLD is associated with a substantial increase in risk for type 2 diabetes^[@bibr3-1756283X17725977]^ and cardiovascular disease.^[@bibr4-1756283X17725977]^ Consequently, approaches aimed at modifying risk factors for NAFLD are urgently in need to prevent or delay its onset as well as to limit its health-related burden.

Metabolic disorders characterized by insulin resistance including type 2 diabetes and central obesity have been well identified as significant contributing factors for NAFLD.^[@bibr5-1756283X17725977]^ Large-scale cross-sectional studies have shown that these disorders together with NAFLD are associated with lower levels of physical activity (PA) at any intensity on a daily basis compared with healthy controls.^[@bibr6-1756283X17725977],[@bibr7-1756283X17725977]^ Since increased PA plays a protective role against the development of type 2 diabetes and central obesity as well as against other risk factors related to NAFLD such as hypertension and dyslipidemia,^[@bibr8-1756283X17725977][@bibr9-1756283X17725977][@bibr10-1756283X17725977]--[@bibr11-1756283X17725977]^ it is assumed that increased PA might be also effective in preventing NAFLD. Indeed, in recent years there is a notably growing interest in examining the association between PA and risk of NAFLD,^[@bibr12-1756283X17725977][@bibr13-1756283X17725977][@bibr14-1756283X17725977][@bibr15-1756283X17725977][@bibr16-1756283X17725977][@bibr17-1756283X17725977][@bibr18-1756283X17725977][@bibr19-1756283X17725977][@bibr20-1756283X17725977][@bibr21-1756283X17725977][@bibr22-1756283X17725977][@bibr23-1756283X17725977][@bibr24-1756283X17725977]--[@bibr25-1756283X17725977]^ with most of them demonstrating a significant beneficial effect of PA in preventing NAFLD. However, no systematic reviews or meta-analyses have been conducted to quantify their association to date, which may provide a higher level of evidence than the individual study in general.

In addition, the recent guidelines recommend at least 150 min/week of moderate intensity or 75 min/week of vigorous intensity PA for all adults to reduce the risk of cardiovascular disease and type 2 diabetes as well as to improve cardiorespiratory fitness.^[@bibr26-1756283X17725977],[@bibr27-1756283X17725977]^ They further point out that additional health benefits can occur with extra PA, which might act in a dose--response manner.^[@bibr27-1756283X17725977]^ However, it remains unknown whether the guideline-recommended minimum levels of PA, which are approximately equal to a minimal exercise amount of 500 metabolic equivalent (MET)-minutes/week,^[@bibr26-1756283X17725977],[@bibr27-1756283X17725977]^ are also sufficient to reduce the risk of NAFLD, and if there exists a dose--response relationship.

Therefore, the aims of the present study were to quantify the association between PA and risk of NAFLD in adults by meta-analyzing the observational studies and using dose--response analysis, as well as to explore the potential sources of heterogeneity that would affect the association by subgroup and meta-regression analyses.

Methods {#section6-1756283X17725977}
=======

This meta-analysis was reported in accordance with the Meta-analysis Of Observational Studies in Epidemiology (MOOSE) guidelines, and adhered to a predesigned protocol (PROSPERO CRD42016041233).

Search strategy {#section7-1756283X17725977}
---------------

Studies of interest were identified by searching the electronic databases of *PubMed, Web of Science*, and the *Cochrane Library* from their inception through January, 2017 using words related to 'physical activity' (e.g. exercise, motor activity, sedentary lifestyle, metabolic equivalent\*, physical activit\*, inactivity, walking, training, running, cycling) and 'nonalcoholic fatty liver disease' (e.g. NAFLD, non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, non-alcoholic steatohepatitis, steatosis, NAFLD, NASH). Reference lists from relevant major reviews and retrieved eligible articles were scrutinized to identify additional studies.

Inclusion and exclusion criteria {#section8-1756283X17725977}
--------------------------------

Studies written in English were included if they fulfilled the following criteria: (1) observational studies using a cohort or case-control design; (2) adult populations with ages ⩾18 years; (3) outcome of interest was NAFLD that includes simple steatosis and nonalcoholic steatohepatitis but not the late stage liver diseases such as cirrhosis or hepatocellular carcinoma; and (4) effect estimates \[i.e. relative risk (RR), odds ratio (OR)\] of NAFLD associated with PA were provided or could be calculated. The diagnosis of NAFLD had to be defined with reference to the standard guidelines using noninvasive or invasive approaches.^[@bibr2-1756283X17725977],[@bibr5-1756283X17725977]^ Studies were excluded if they enrolled populations with secondary causes of hepatic steatosis such as alcohol, medication, and hepatitis viruses, or their effect estimates of interest could not be calculated.

Data extraction and quality assessment {#section9-1756283X17725977}
--------------------------------------

A predesigned data collection form was used to extract the following information: first author, publication year, mean age, mean body mass index (BMI), proportion of men, geographical region, effect estimate with 95% confidence intervals (CIs) of the association between PA and NAFLD risk, number of cases and noncases (or controls), duration of follow-up, type and level of PA, method for ascertainment of NAFLD, and confounders adjusted.

The methodological quality of each included cohort study or case-control was assessed using the 9-stars-Newcastle-Ottawa scale.^[@bibr28-1756283X17725977]^ All the data extraction and quality assessment were extracted and carefully checked by two independent authors (S.Q. and X.C.). If discrepancies occurred, they were solved by discussion referring back to the original studies.

Data synthesis and statistical analysis {#section10-1756283X17725977}
---------------------------------------

For studies that provided only multiple levels of PA with distributions of cases and noncases, unadjusted effect estimates with 95% CIs were calculated directly.^[@bibr29-1756283X17725977]^ For studies that reported effect estimates with or without adjustment for possible confounders, the maximally adjusted ones were selected for the primary analysis. For studies that assessed the association of NAFLD with different types of PA, data related to the leisure-time PA were initially chosen. For studies that reported sex-specific data, they were included as separate studies. In this meta-analysis, the RR, which was considered equivalent to the hazard ratio, was used for cohort studies, while the OR was employed for case-control studies. To assess the association of PA with NAFLD risk, both categorical and dose--response meta-analyses were conducted.

For categorical analysis, four levels of PA were generated as previously suggested: highest, moderate, light, and lowest.^[@bibr30-1756283X17725977]^ Briefly, the highest and lowest PA levels corresponded to the highest and lowest groups in the included studies, respectively; and the moderate or light ones corresponded to the second and third-highest groups in studies that had more than two exposure categories, respectively. The overall estimates with 95% CIs for the associations of NAFLD with different PA levels *versus* the lowest one were calculated using a random-effects meta-analysis model, a model that is considered to be more conservative than the fixed-effects one.^[@bibr31-1756283X17725977]^

For dose--response analysis, the generalized least-squares trend estimation method described by Greenland and Longnecker was used.^[@bibr32-1756283X17725977]^ The median of PA level expressed in MET-minutes/week for each category was assigned to the corresponding effect estimate. For studies that did not report the medians, they were imputed using the midpoints of the lower and upper bounds. For studies with an open-ended highest PA category, the width of PA in this category was assumed to be equal to that of its closest adjacent category.^[@bibr30-1756283X17725977]^ For studies reporting the PA intensity without specification, the light, moderate, and vigorous intensity was respectively defined as 3, 5, and 9 METs.^[@bibr30-1756283X17725977]^ Both the linear and nonlinear associations were assessed using a two-stage random-effects dose--response analysis. The nonlinear association was assessed by modeling the PA level with the use of restricted cubic splines with three knots at the 10th, 50th, and 90th percentiles of the exposure data. A *p*-value for nonlinearity was calculated using a null hypothesis that the coefficient of the second spline was equal to zero.

Heterogeneity was evaluated using the Cochran Q statistic and *I^2^* metric, with *p*-value for Cochran Q statistic \<0.10 or *I^2^*-value \>50% representing statistical heterogeneity. The source of heterogeneity was assessed using subgroup analyses based on type of PA, validation of PA questionnaire, and adjustment for covariates. It was further assessed by meta-regression analyses of age (logarithmic transformed), sex (proportion of men), BMI, and duration of follow-up (if possible). Sensitivity analyses were performed by removing each study individually from the primary meta-analysis. Publication bias was evaluated by funnel plot asymmetry, and further assessed using Begg's rank correlation test and Egger's regression asymmetry test, with *p* \< 0.10 indicative of significance. All the above statistical analyses were conducted using Stata Software (version 12.0 StataCorp, College Station, TX, USA).

Results {#section11-1756283X17725977}
=======

Characteristics of included studies {#section12-1756283X17725977}
-----------------------------------

The details of the literature search and study selection are shown in [Figure 1](#fig1-1756283X17725977){ref-type="fig"}. Of the 1510 unique articles retrieved, 8 fulfilled the predefined inclusion criteria.^[@bibr18-1756283X17725977][@bibr19-1756283X17725977][@bibr20-1756283X17725977][@bibr21-1756283X17725977][@bibr22-1756283X17725977][@bibr23-1756283X17725977][@bibr24-1756283X17725977]--[@bibr25-1756283X17725977]^ Among them, two had sex-specific data.^[@bibr22-1756283X17725977],[@bibr24-1756283X17725977]^ As a result, 10 studies were included in the meta-analysis, with 6 cohort^[@bibr18-1756283X17725977][@bibr19-1756283X17725977][@bibr20-1756283X17725977][@bibr21-1756283X17725977]--[@bibr22-1756283X17725977]^ and 4 case-control studies.^[@bibr23-1756283X17725977][@bibr24-1756283X17725977]--[@bibr25-1756283X17725977]^

![Flow diagram of literature search.\
^a^The studies by Hashimoto and colleagues^[@bibr22-1756283X17725977]^ and Noto and colleagues^[@bibr24-1756283X17725977]^ had sex-based data.](10.1177_1756283X17725977-fig1){#fig1-1756283X17725977}

The characteristics of the included studies are described in [Table 1](#table1-1756283X17725977){ref-type="table"}. All studies were published between 2014 and 2016. For cohort studies, there were 32,657 incident NAFLD cases identified from 142,781 participants, who had a mean BMI of 22.6 kg/m^2^ (ranged from 21.6 to 24.4 kg/m^2^) at baseline, during a mean follow-up period of 6.30 years. For case-control studies, there were a total of 382 NAFLD cases and 302 controls. Most of these studies were conducted in Asian countries, and the others in European countries. All studies utilized questionnaires for assessment of PA, and the majority of them used ultrasonography for ascertainment of NAFLD except two using liver biopsy.^[@bibr24-1756283X17725977]^ Overall, five studies provided effect estimates adjusted for confounding factors, although the consideration of these factors was different from each study. The methodological quality of included cohort studies was high, with a mean score of 7.7.

###### 

Characteristics of included studies in this meta-analysis.

![](10.1177_1756283X17725977-table1)

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study                                                  Age (y), sex^[a](#table-fn2-1756283X17725977){ref-type="table-fn"}^, %   Total\        Categories of PA levels^[b](#table-fn3-1756283X17725977){ref-type="table-fn"}^   Adjusted covariates
                                                                                                                                  sample size                                                                                    
  ------------------------------------------------------ ------------------------------------------------------------------------ ------------- -------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Cohort studies                                                                                                                                                                                                                 

  Tsunoda et al.,^[@bibr18-1756283X17725977]^ Japan      47.8,\                                                                   7803          Cat 1: PA ⩾ 3 times/week\                                                        Age, sex, BMI, alcohol consumption (never or low-moderate), smoking, family history of liver disease, alanine transaminase, γ-glutamyltransferase, hypertension, diabetes, dyslipidemia, vegetable intake, other intensity types of PA and propensity
                                                         39.5                                                                                   Cat 2: PA 2 times/week\                                                          
                                                                                                                                                Cat 3: PA 1 times/week\                                                          
                                                                                                                                                Cat 4: PA \< 1 times/week                                                        

  Sung et al.,^[@bibr19-1756283X17725977]^ Korea         40.5,\                                                                   126,811       Cat 1: PA sessions/week ⩾ 5\                                                     Age, sex, center, year of screening exam, smoking status, alcohol intake, education level, BMI, diabetes, hypertension, cardiovascular disease, and change in BMI between baseline and follow up
                                                         47                                                                                     Cat 2: PA sessions/week 3--4\                                                    
                                                                                                                                                Cat 3: PA sessions/week 1--2\                                                    
                                                                                                                                                Cat 4: PA sessions/week 0                                                        

  Kwak et al.,^[@bibr20-1756283X17725977]^ Korea         51.4,\                                                                   1373          Cat 1: ⩾1504 MET-min/week (men)\                                                 Age, sex, BMI, smoking, hypertension, diabetes, soft drink consumption, coffee consumption, change in waist circumference during follow up, visceral adipose tissue area, subcutaneous adipose tissue area, and HOMA-IR
                                                         51.6                                                                                   ⩾1368 MET-min/week (women)\                                                      
                                                                                                                                                Cat 2: 1004--1500 MET-min/week (men)\                                            
                                                                                                                                                912--1365 MET-min/week (women)\                                                  
                                                                                                                                                Cat 3: 522--996 MET-min/week (men)\                                              
                                                                                                                                                486--900 MET-min/week (women)\                                                   
                                                                                                                                                Cat 4: 10--547 MET-min/week (men)\                                               
                                                                                                                                                68--480 MET-min/week (women)\                                                    
                                                                                                                                                Cat 5: Inactive                                                                  

  Li et al.,^[@bibr21-1756283X17725977]^\                36.7,\                                                                   2367          Cat 1: PA everyday\                                                              None
  China                                                  100                                                                                    Cat 2: PA often\                                                                 
                                                                                                                                                Cat 3: PA occasionally\                                                          
                                                                                                                                                Cat 4: PA never or seldom                                                        

  Hashimoto et al.,^[@bibr22-1756283X17725977]^ Japan                                                                                                                                                                            

   Women                                                 41.4,\                                                                   1847          Cat 1: Regular PA\                                                               None
                                                         0                                                                                      Cat 2: No regular PA                                                             

   Men                                                   42.4,\                                                                   2580                                                                                           
                                                         100                                                                                                                                                                     

  Case-control studies                                                                                                                                                                                                           

  Miele et al.,^[@bibr23-1756283X17725977]^ Italy        51.5,\                                                                   280           Cat 1: \>1 activity/week\                                                        Age, drinking habits, additional use of salt, meat intake, and PA
                                                         64.5                                                                                   Cat 2: ⩽1 activity/week                                                          

  Noto et al.,^[@bibr24-1756283X17725977]^ Japan                                                                                                                                                                                 

   Women                                                 57.7,\                                                                   119           Cat 1: Regular PA\                                                               None
                                                         0                                                                                      Cat 2: No regular PA                                                             

   Men                                                   46.7,\                                                                   130                                                                                            
                                                         100                                                                                                                                                                     

  Katsagoni et al.,^[@bibr25-1756283X17725977]^ Greece   45.2,\                                                                   155           PA as a continuous variable                                                      Age, sex, waist circumference, HOMA-IR, adiponectin, and TNF-α
                                                         68.4                                                                                                                                                                    
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

BMI, body mass index; HOMA-IR, homeostatic model assessment of insulin resistance; MET, metabolic equivalent; PA, physical activity; TNF-α, tumor necrosis factor-α.

Data represented proportions of men.

Four categories of PA levels were generated, which were highest, moderate, light, and lowest. For each included study, the highest and lowest PA categories corresponded to the highest and lowest groups, respectively. For studies with ⩾3 PA categories, the second and third-highest PA categories corresponded to the moderate and light groups, respectively.

PA and NAFLD risk in cohort studies {#section13-1756283X17725977}
-----------------------------------

***Categorical analysis***: The associations between different PA levels and NAFLD risk among adults are shown in [Figure 2](#fig2-1756283X17725977){ref-type="fig"}. Compared with the lowest PA level, which was defined as physically inactive or sedentary in the included studies, the highest PA level was associated with a decreased risk of NAFLD (six studies; RR 0.79, 95% CI 0.71--0.89; *I^2^* = 59.1%). The moderate and light PA levels were also associated with reduced risks of NAFLD compared with the lowest one (four studies; RR 0.87, 95% CI 0.83--0.91, *I^2^* \<1%, and four studies; RR 0.93, 95% CI 0.90--0.96, *I^2^* \<1%; respectively). Further analysis using the test for interaction suggested that the highest and moderate PA levels were superior to the light one in lowering NAFLD risk (*p*~for\ interaction~ = 0.006 and 0.02, respectively).

![Pooled estimates of the relative risks of NAFLD associated with PA.\
CI, confidence interval; NAFLD, nonalcoholic fatty liver disease; PA, physical activity.\
^a^Data were averaged from all the three groups with different PA intensities.](10.1177_1756283X17725977-fig2){#fig2-1756283X17725977}

Subgroup, meta-regression, and sensitivity analyses as well as publication bias that evaluated the association between the highest PA level (*versus* the lowest one) and NAFLD risk were conducted as follows. Subgroup analyses showed that the association was more conservative in studies using validated PA questionnaires (RR 0.78, 95% CI 0.68--0.89) than those who did not (RR 0.89, 95% CI 0.58--1.37), and seemed to be unlikely to be affected by the types of PA (leisure-time *versus* total PA, *p*~for\ interaction~ = 0.28; [Table 2](#table2-1756283X17725977){ref-type="table"}). This association remained significant after adjusting for a single traditional risk factor for NAFLD including smoking, obesity, glucose control, blood pressure, or lipid profiles, as well as for a cluster of them (all *p* \<0.05; [Table 2](#table2-1756283X17725977){ref-type="table"}). Interestingly, the strength of this association tends to be weaker in studies that take into account changes of BMI during the follow-up period compared with those who did not (*p*~for\ interaction~ = 0.16; [Table 2](#table2-1756283X17725977){ref-type="table"}).

###### 

Subgroup analyses of relative risk of NAFLD for highest *versus* lowest PA level in cohort studies.

![](10.1177_1756283X17725977-table2)

  Variable                                                                                                        Number of studies   Effect estimates   Heterogeneity          
  --------------------------------------------------------------------------------------------------------------- ------------------- ------------------ --------------- ------ ------
  Sex                                                                                                                                                                           
   Male                                                                                                           2                   0.90               0.59--1.36      79.2   0.03
   Female                                                                                                         1                   0.74               0.55--1.01      NA     NA
  Mixed                                                                                                           3                   0.77               0.66--0.91      70.4   0.03
  PA type^[a](#table-fn5-1756283X17725977){ref-type="table-fn"}^                                                                                                                
   TPA                                                                                                            1                   0.66               0.46--0.94      NA     NA
   LTPA                                                                                                           5                   0.81               0.72--0.90      57.5   0.05
  PA assessment                                                                                                                                                                 
   Validated                                                                                                      4                   0.78               0.68--0.89      52.8   0.10
   Not validated                                                                                                  2                   0.89               0.58--1.37      80.9   0.02
  Adjustment                                                                                                                                                                    
   Yes                                                                                                            3                   0.77               0.66--0.91      70.4   0.03
   No                                                                                                             3                   0.83               0.66--1.05      60.1   0.08
  Adjusted for ...                                                                                                                                                              
  \(1\) Smoking                                                                                                                                                                 
   Yes                                                                                                            3                   0.77               0.66--0.91      70.4   0.03
   No                                                                                                             3                   0.83               0.66--1.05      60.1   0.08
  \(2\) Body mass index/obesity                                                                                                                                                 
   Yes                                                                                                            3                   0.77               0.66--0.91      70.4   0.03
   No                                                                                                             3                   0.83               0.66--1.05      60.1   0.08
  \(3\) Glucose control/diabetes                                                                                                                                                
   Yes                                                                                                            3                   0.77               0.66--0.91      70.4   0.03
   No                                                                                                             3                   0.83               0.66--1.05      60.1   0.08
  \(4\) Blood pressure/hypertension                                                                                                                                             
   Yes                                                                                                            2                   0.71               0.58--0.86      23.3   0.25
   No                                                                                                             4                   0.83               0.73--0.95      53.6   0.09
  \(5\) Lipid profiles/dyslipidemia                                                                                                                                             
   Yes                                                                                                            2                   0.71               0.58--0.86      23.3   0.25
   No                                                                                                             4                   0.83               0.73--0.95      53.6   0.09
  \(6\) A cluster of at least 3 traditional risk factors^[b](#table-fn6-1756283X17725977){ref-type="table-fn"}^                                                                 
   Yes                                                                                                            3                   0.77               0.66--0.91      70.4   0.03
   No                                                                                                             3                   0.83               0.66--1.05      60.1   0.08
  \(7\) Changes in body mass index during follow-up period                                                                                                                      
   Yes                                                                                                            1                   0.86               0.80--0.92      NA     NA
   No                                                                                                             5                   0.77               0.67--0.88      44.7   0.12

CI, confidence interval; LTPA, leisure-time physical activity; NA, not applicable; NAFLD, nonalcoholic fatty liver disease; PA, physical activity; RR, relative risk; TPA, total physical activity.

The study from Kwak and colleagues reported data on TPA and LTPA, but in this subgroup analysis data from TPA were chosen.^[@bibr20-1756283X17725977]^

The traditional risk factors included metabolic factors related to obesity, diabetes, hypertension, or dyslipidemia.

Meta-regression analyses suggested that the association was statically moderated by age (*β* coefficient 0.30, *p* = 0.04), but was not affected by sex (*β* coefficient 1.00, *p* = 0.54), BMI (*β* coefficient 1.10, *p* = 0.30), or follow-up periods (*β* coefficient 0.98, *p* = 0.59). Sensitivity analysis by removing each individual study showed that the primary RRs were unlikely to be substantially altered. The shape of the funnel plot seems to be asymmetrical ([Figure 3](#fig3-1756283X17725977){ref-type="fig"}), but no statistical publication bias was detected using the Begg's (*p* = 0.71) or Egger's test (*p* = 0.49).

![Funnel plot with pseudo 95% CIs for publication bias in studies of the association between PA and risk of NAFLD.\
CI, confidence interval; NAFLD, nonalcoholic fatty liver disease; PA, physical activity.](10.1177_1756283X17725977-fig3){#fig3-1756283X17725977}

***Dose--response analysis***: Only two cohort studies^[@bibr19-1756283X17725977],[@bibr20-1756283X17725977]^ allowed the quantitative estimation of PA in MET-minutes/week. The departure from a log-linear association between PA and risk of NAFLD among adults was not significant (*p* for nonlinearity = 0.10, and for linearity \<0.001; [Figure 4](#fig4-1756283X17725977){ref-type="fig"}). Pooled results showed that a 500 MET-minutes/week incrementally higher PA was associated with an 18% risk reduction of NAFLD (RR 0.82, 95% CI 0.73--0.91), and the magnitude of this reduction continued to be enlarged with more PA when compared with 500 MET-minutes/week PA \[e.g. 1000 MET-minutes/week led to an 33% risk reduction (RR 0.67, 95% CI 0.54--0.83, *p*~for\ interaction~ = 0.10)\].

![Dose--response association between PA assessed by metabolic equivalent-min/week and risk of NAFLD.\
MET, metabolic equivalent; NAFLD, nonalcoholic fatty liver disease; PA, physical activity.\
The solid and dotted splines of the graph indicate the pooled relative risk and 95% confidence intervals, respectively.](10.1177_1756283X17725977-fig4){#fig4-1756283X17725977}

PA and NAFLD risk in case-control studies {#section14-1756283X17725977}
-----------------------------------------

***Categorical analysis***: A total of three studies provided data comparing the risk of NAFLD with the assigned highest *versus* lowest PA level, and the pooled result showed that the highest PA level significantly reduced the risk of NAFLD (OR 0.43, 95% CI 0.27--0.68; *I^2^* \< 1%). Subgroup analysis suggested that this association was similar across different types of PA (recreational *versus* leisure-time PA, *p*~for\ interaction~ = 0.81) or methods for NAFLD diagnosis (ultrasonography *versus* liver biopsy, *p*~for\ interaction~ = 0.81). Sensitivity analysis by excluding one study at a time showed that the primary association was not statistically influenced by any particular study. There was no significant evidence of publication bias as indicated by the Begg's (*p* = 0.30) or Egger's test (*p* = 0.27).

***Dose--response analysis***: Since none of the case-control studies provided individual effect sizes corresponding to at least three different levels of PA, assessment of the linear or nonlinear association of NAFLD risk with PA seemed to be impossible. Yet the study by Katsagoni and colleagues, who reported data using PA level as the continuous variable,^[@bibr25-1756283X17725977]^ suggested that the odds of having NAFLD was reduced by 26% for every 100 MET-minutes/day incrementally higher PA (OR 0.74, 95% CI 0.61--0.89); which is alternatively, a reduction by 19% per 500 MET-minutes/week incrementally higher PA (OR 0.81, 95% CI 0.70--0.92).

Discussion {#section15-1756283X17725977}
==========

Summary of main findings {#section16-1756283X17725977}
------------------------

The present meta-analysis shows that increased PA was associated with a reduced risk of NAFLD among adults, which was consistently observed in cohort and case-control studies. This association seemed to act in a log-linear dose--response manner among adults, and remained statistically significant with adjustment for traditional risk factors for NAFLD, indicating that PA might be an independent protective factor against NAFLD. It further shows that this association was not affected by the types of PA, but was positively moderated by age. Of note, this meta-analysis suggests that the guideline-recommended minimal levels of PA were sufficient for a moderate reduction in NAFLD risk. However, a higher amount of PA may be required in order to obtain a considerable larger risk reduction.

Interpretations {#section17-1756283X17725977}
---------------

Recent guideline suggests that unhealthy lifestyles including physical inactivity play a key role in the development of NAFLD, and that the assessment of PA habits is worth being conducted in a comprehensive NAFLD screening programme.^[@bibr2-1756283X17725977]^ However, such recommendations are largely based on the results from a single population-based cross-sectional study by Gerber and colleagues^[@bibr7-1756283X17725977]^ rather than a meta-analysis or a systematic review, although that study was well-conducted and the conclusion was well-balanced. Therefore, our finding of this meta-analysis that PA might lead to a decreased risk of NAFLD based on results from observational studies and in particular of cohort studies seems to provide higher level of evidence in support of the aforementioned notions.

Recent evidence well-documents that PA is effective in modifying liver fat and serum alanine aminotransferase among patients who already had NAFLD;^[@bibr33-1756283X17725977][@bibr34-1756283X17725977]--[@bibr35-1756283X17725977]^ however, there is so far, no standardized or straightforward recommendation for the amount of PA aiming to prevent NAFLD in current guidelines. The national PA recommendation of engaging in at least 150 min/week of moderate PA or 75 min/week of vigorous activity for adults ^[@bibr26-1756283X17725977],[@bibr27-1756283X17725977]^ has shown to be associated with a substantially reduced risk of cardiovascular disease,^[@bibr36-1756283X17725977]^ heart failure,^[@bibr30-1756283X17725977]^ and type 2 diabetes.^[@bibr27-1756283X17725977]^ Given this evidence and in light of the lowered NAFLD risk related to 500 MET-minutes/week incrementally higher PA as shown in our dose--response analysis, it seems reasonable to prescribe this guideline-recommended minimum PA level for NAFLD prevention in clinical practice. Notably, as evidenced by the categorical and subgroup analyses as well as the log-linear dose--response association, one should be aware that any amount of PA in any type (e.g. leisure-time or recreational PA) is better than physical inactivity, and that the higher the amount of PA, the more the risk reduction of NAFLD. Therefore, interventions with the aim to increase PA, such as using pedometers,^[@bibr37-1756283X17725977]^ might be worth recommending. Yet as suggested by Finelli and Tarantino, one should also keep in mind that PA requires to be maintained for long periods (e.g. months or years) at an increased level in order to counteract the development or progression of NAFLD.^[@bibr38-1756283X17725977]^

Several lines of evidence recently suggest that there might be a sex difference in the association between PA and risk of fatty liver including NAFLD.^[@bibr24-1756283X17725977],[@bibr39-1756283X17725977]^ But, their findings were inconsistent. Our results as indicated by the subgroup and meta-regression analyses therefore provided a piece of evidence in addressing this concern, showing that men did not substantially differ from women regarding the NAFLD risk reduction from PA. Interestingly, our results showed that the magnitude of risk reduction of NAFLD was larger in participants with older age. This is definitely encouraging since older participants experience a higher chance of developing NAFLD^[@bibr40-1756283X17725977]^ and are more likely to show impaired physical capacity compared with younger ones. Moreover, although independent of changes in BMI during the follow-up period, the strength of the association between PA and NAFLD risk became weaker when considering it as a possible confounder. This may partly imply the important role of weight change in altering NALFD risk.

Despite a statistically nonsignificant difference between studies using validated questionnaires and those not regarding the association of PA with risk of NALFD, our subgroup analysis showed that the former exhibited a more conservative and stronger association than the latter. This might indicate that studies failing to use validated PA questionnaires would probably underestimate the observed association of PA with risk of NAFLD. In contrast to the methods for PA assessment, our results from the case-control studies did not provide adequate evidence that the risk of NAFLD associated with PA would be significantly affected by approaches for NAFLD ascertainment (that is, liver biopsy *versus* ultrasonography), although it is well established that liver biopsy outperforms ultrasonography in diagnosing NALFD^[@bibr41-1756283X17725977]^ and is considered to be the gold standard for characterizing liver histology and to stage fibrosis.^[@bibr2-1756283X17725977]^

There are several potential mechanisms that may underlie the observed inverse association between PA and risk of NAFLD. Firstly, some studies have noted that PA might improve appetite control by enhancing satiety signaling;^[@bibr42-1756283X17725977]^ whereas a good appetite is closely associated with a high-calorie or excess fat intake and obesity, which have been recognized to be central to the development of NAFLD.^[@bibr2-1756283X17725977]^ Secondly, PA not only reduces free fatty acids in circulation but also increases the uptake and utilization of fatty acids in liver and skeletal muscle,^[@bibr33-1756283X17725977],[@bibr43-1756283X17725977]^ leading to subsequently reduced hepatic fat accumulation. Thirdly, hepatic and muscle insulin resistance is considered the pathophysiological hallmark of NAFLD,^[@bibr44-1756283X17725977]^ which could be ameliorated directly by increased PA probably through a reduction in hepatic fat content^[@bibr45-1756283X17725977]^ or indirectly through an increase in muscle glucose transporter 4 expression and muscle glycogen synthase activity.^[@bibr46-1756283X17725977]^

Strengths and limitations {#section18-1756283X17725977}
-------------------------

The primary strength of our study is that the large sample size from case-control and prospective cohort studies increases the statistical power to detect the association between PA and NAFLD risk. In addition, the dose--response analysis allowed us to investigate the shape of the possible association. Moreover, the main findings observed in our study were robust as indicated by the sensitivity analyses, and the existing heterogeneities could be explained by age or partly by other variables like the validation of PA questionnaires and the adjusted covariates including blood pressure, lipid profiles, and changes in BMI.

However, several possible limitations of our study should be mentioned. Firstly, despite of the maximally adjusted effect estimates chosen for the primary analysis, results from the meta-analysis cannot prove causality since they are subject to residual confounding. Our meta-analysis showed that the association of NAFLD risk with PA was unlikely to be affected by any single one or a cluster of the traditional risk factors for NAFLD including smoking, obesity, glucose control, blood pressure, and lipid profiles. However, we cannot further explore the potential influences from other confounding factors related to unhealthy lifestyle behaviors (e.g. prolonged sedentary time^[@bibr15-1756283X17725977]^) and healthy ones (e.g. high coffee consumption^[@bibr47-1756283X17725977],[@bibr48-1756283X17725977]^) because of the fact that the majority of included studies failed to provide such data.

Secondly, both unadjusted and the maximally adjusted estimates were pooled together in our meta-analysis, which may contribute to the existing heterogeneity, despite that there was a nonsignificant difference between them. Thirdly, although validated questionnaires had been used in most cohort studies to assess PA levels, they might still not reflect the true ones. This lies in the fact that subjectively measured PA (e.g. by questionnaires) is more likely to be subject to recall and response bias compared with the objectively measured one (e.g. by pedometers), resulting in underestimated or overestimated PA levels.^[@bibr49-1756283X17725977]^ This might lead to a risk of misclassification bias. Fourthly, there is evidence that both aerobic and resistance exercise exert beneficial effects against the risk of NAFLD. However, the small number of included studies limited our further analysis on this topic. Fifthly, as all the cohort studies were exclusively from Asian origins, our main findings might be not representative for other populations like Whites or Hispanics who might have a different ethnical and genetic background. Furthermore, our study did not provide results regarding the association of PA with risks of NAFLD subtypes like nonalcoholic steatohepatitis, but there is epidemiological evidence from the cross-sectional study that increased PA might be correlated with a reduced OR of having nonalcoholic steatohepatitis.^[@bibr50-1756283X17725977]^ Finally, the inclusion of only English-language and published studies might introduce some selection and publication bias. Moreover, the statistical power of the publication bias assessment and meta-regression analyses might be weakened because of the limited number of studies included.

In conclusion, our meta-analysis indicated that increased PA might be dose-dependently associated with a lower risk of NAFLD in adults. The current guideline-recommended minimum PA level (500 MET-minutes/week) was able to moderately reduce NAFLD risk; however, doses of PA in excess of that suggested amount might be required to obtain a more robust risk reduction. Future studies with large-scale prospective cohort designs are required to explore the association of risk for NAFLD and in particular its subtype nonalcoholic steatohepatitis with objectively measured PA levels or at least self-reported ones assessed by validated questionnaires, where PA levels are categorized into aerobic or resistance types, among sex-based or age-stratified populations.
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